Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1645 1648 1671
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18712809 | IMMUNOGENIC COMPOSITIONS AND THEIR USES | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18274741 | COMPOSITIONS AND METHODS FOR PRODUCING GLYCO-MODIFIED VIRAL ANTIGENS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18286025 | METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18701892 | DNA ORIGAMI SUBUNIT VACCINE FOR PREVENTION OF SARS-CoV-2 VARIANT INFECTION | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18701890 | HIGH SENSITIVITY DNA LINKED IMMUNOSORBENT SIGNAL AMPLIFICATION ASSAY (DLISA) FOR DETECTION OF INFECTIOUS SARS-COV-2 VIRUS AND VARIANTS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18686928 | VACCINE COMPOSITION FOR PREVENTION AGAINST COVID-19 | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18359154 | SELF-ASSSEMBLING NANOSTRUCTURE VACCINES | Final Rejection | University of Washington |
| 18030465 | DETECTION OF ACE2 IgM AUTOANTIBODIES AS MARKERS OF SEVERITY AND MECHANISM IN COVID19 PATIENTS | Non-Final OA | The Johns Hopkins University |
| 18699034 | CORONAVIRUS VACCINES | Non-Final OA | Cambridge Enterprise Limited |
| 18627824 | MULTIVALENT INFLUENZA VACCINES | Non-Final OA | SANOFI PASTEUR INC. |
| 17280377 | COMBINED IMMUNIZATION AGAINST MENINGOCOCCAL DISEASE AND HUMAN PAPILLOMAVIRUS | Non-Final OA | Sanofi Pasteur Inc. |
| 18699219 | PEPTIDE TARGETING FUSOBACTERIA, COMPOSITION FOR DIAGNOSING CANCER COMPRISING SAME, AND DRUG DELIVERY COMPOSITION | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 17776828 | CODON OPTIMIZED NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 18579769 | METHOD OF TREATING DRUG RESISTANT ESKAPEE PATHOGENS USING THERAPEUTIC BACTERIOPHAGES | Non-Final OA | The Government of the United States, as Represented by the Secretary of the Army |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | Non-Final OA | Inovio Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy